Posted by Michael Wonder on 22 Jul 2021
Biogen sees heavy patient interest in new Alzheimer’s drug
22 July 2021 - Company pushed back against criticism of drug’s effectiveness and approval, saying trial data supported use.
Biogen has defended its new Alzheimer’s disease drug, Aduhelm, in the midst of a controversy over its approval last month that threatens to slow patient uptake and insurance reimbursement of the potential blockbuster product.
